Regeneron Pharmaceuticals 관리

관리 기준 확인 3/4

Regeneron Pharmaceuticals CEO는 Leonard Schleifer, Jan1988 에 임명되었습니다 의 임기는 36.92 년입니다. 총 연간 보상은 $ 8.18M, 22.9% 로 구성됩니다. 22.9% 급여 및 77.1% 보너스(회사 주식 및 옵션 포함). 는 $ 1.68B 가치에 해당하는 회사 주식의 2.23% 직접 소유합니다. 1.68B. 경영진과 이사회의 평균 재임 기간은 각각 7.3 년과 18 년입니다.

주요 정보

Leonard Schleifer

최고 경영자

US$8.2m

총 보상

CEO 급여 비율	22.9%
CEO 임기	36.9yrs
CEO 소유권	2.2%
경영진 평균 재임 기간	7.3yrs
이사회 평균 재임 기간	18yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Leonard Schleifer 의 보수는 Regeneron Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	US$5b
Jun 30 2024	n/a	n/a	US$4b
Mar 31 2024	n/a	n/a	US$4b
Dec 31 2023	US$8m	US$2m	US$4b
Sep 30 2023	n/a	n/a	US$4b
Jun 30 2023	n/a	n/a	US$4b
Mar 31 2023	n/a	n/a	US$4b
Dec 31 2022	US$7m	US$2m	US$4b
Sep 30 2022	n/a	n/a	US$5b
Jun 30 2022	n/a	n/a	US$6b
Mar 31 2022	n/a	n/a	US$8b
Dec 31 2021	US$6m	US$2m	US$8b
Sep 30 2021	n/a	n/a	US$7b
Jun 30 2021	n/a	n/a	US$6b
Mar 31 2021	n/a	n/a	US$4b
Dec 31 2020	US$135m	US$1m	US$4b
Sep 30 2020	n/a	n/a	US$3b
Jun 30 2020	n/a	n/a	US$3b
Mar 31 2020	n/a	n/a	US$2b
Dec 31 2019	US$21m	US$1m	US$2b
Sep 30 2019	n/a	n/a	US$2b
Jun 30 2019	n/a	n/a	US$2b
Mar 31 2019	n/a	n/a	US$2b
Dec 31 2018	US$27m	US$1m	US$2b

보상 대 시장: Leonard 의 총 보상 ($USD 8.18M )은 UK 시장( $USD 5.74M ).

보상과 수익: Leonard 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Leonard Schleifer (71 yo)

36.9yrs

테뉴어

US$8,184,338

보상

Dr. Leonard S. Schleifer, M.D., Ph D., Co-founded Regeneron Pharmaceuticals, Inc. in 1988 and has been its President and Chief Executive Officer since 1988 and is its Board Co-Chair since June 2023. He ser...

리더십 팀

이름	위치	테뉴어	보상	소유권
Leonard Schleifer	Co-Founder	36.9yrs	US$8.18m	2.23% $ 1.7b
George Yancopoulos	Co-Founder	23.9yrs	US$7.76m	1.07% $ 810.6m
Andrew Murphy	Executive Vice President of Research	5.9yrs	US$8.43m	0.050% $ 37.5m
Daniel Van Plew	Executive VP and GM of Industrial Operations & Product Supply	16.7yrs	US$8.76m	0.033% $ 25.2m
Christopher Fenimore	Senior VP of Finance & CFO	less than a year	데이터 없음	0.018% $ 13.9m
Patrice Gilooly	Senior Vice President of Quality Assurance & Operations	4.9yrs	데이터 없음	데이터 없음
Bob McCowan	Senior VP of IT & Chief Information Officer	3.9yrs	데이터 없음	데이터 없음
Ryan Crowe	Senior Vice President of Investor Relations & Strategic Analysis	no data	데이터 없음	데이터 없음
Joseph LaRosa	Executive VP	13.3yrs	US$7.13m	0.037% $ 27.7m
Melissa Lozner	Senior VP & Chief Compliance Officer	1.9yrs	데이터 없음	데이터 없음
Christina Chan	Senior Vice President of Corporate Affairs	no data	데이터 없음	데이터 없음
Sally Paull	Executive Vice President of Human Resources	8.7yrs	데이터 없음	데이터 없음

7.3yrs

평균 재임 기간

64.5yo

평균 연령

경험이 풍부한 관리: 0R2M 의 관리팀은 노련하고 경험 (평균 재직 기간 7.3 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Leonard Schleifer	Co-Founder	36.9yrs	US$8.18m	2.23% $ 1.7b
George Yancopoulos	Co-Founder	23.9yrs	US$7.76m	1.07% $ 810.6m
Christine Poon	Lead Independent Director	14.1yrs	US$748.01k	0.00073% $ 551.8k
Arthur Ryan	Independent Director	21.9yrs	US$724.99k	0.016% $ 12.4m
Michael Brown	Independent Director	33.5yrs	US$728.99k	0.012% $ 8.8m
Joseph Goldstein	Independent Director	33.5yrs	US$709.99k	0.0046% $ 3.5m
George Sing	Independent Director	36.9yrs	US$724.99k	0.026% $ 20.0m
N. Coles	Independent Director	7.9yrs	US$704.99k	0.000010% $ 7.6k
Craig Thompson	Independent Director	2.2yrs	US$247.79k	0% $ 0
Huda Zoghbi	Independent Director	8.3yrs	US$714.99k	0% $ 0
Bonnie Bassler	Independent Director	8.3yrs	US$709.99k	0.0013% $ 967.6k
Kathryn Guarini	Independent Director	1.3yrs	US$1.03m	0% $ 0

18.0yrs

평균 재임 기간

71yo

평균 연령

경험이 풍부한 이사회: 0R2M 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 18 년).

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2024/12/31 10:04
장 마감 주가	2024/12/30 00:00
수익	2024/09/30
연간 수익	2023/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Regeneron Pharmaceuticals, Inc. 68 애널리스트 중 24 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Jasper Hellweg	Argus Research Company
Brian Skorney	Baird
Ishan Majumdar	Baptista Research

Regeneron Pharmaceuticals 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Senior VP of Finance & CFO recently sold US$6.4m worth of stock

Insider recently sold US$5.6m worth of stock

Regeneron Pharmaceuticals, Inc., Annual General Meeting, Jun 14, 2024

Insider recently sold US$7.6m worth of stock

Regeneron Pharmaceuticals, Inc. Appoints Jason Pitofsky as Controller, Expects to Occur on February 5, 2024

Recent updates

Regeneron Pharmaceuticals, Inc. to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-Concept Results

Regeneron Pharmaceuticals, Inc. Announces EYLEA HD Injection 8 mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision with Extended Dosing Intervals in Patients with Macular Edema following Retinal Vein Occlusion

Odronextamab Ash Presentations Underscore Impressive Potential in Early Lines of Treatment and Additional Types of Lymphoma

Regeneron Pharmaceuticals, Inc. Announces that Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieve Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Review the Resubmission of the Supplemental Biologics License Application for Dupixent®?

Regeneron Pharmaceuticals, Inc. to Present Hematology Pipeline Data At Ash 2024 Annual Meeting

Regeneron Pharmaceuticals, Inc. and Sanofi Receive European Union Approval For Dupixent In Young Children With Eosinophilic Esophagitis

Third quarter 2024 earnings released: EPS: US$12.40 (vs US$9.48 in 3Q 2023)

Regeneron Pharmaceuticals, Inc. Announces Positive Three-Year (156-Week) Data for EYLEA HD® (Aflibercept) Injection 8 mg from an Extension Study of the Phase 3 PHOTON Trial in Patients with Diabetic Macular Edem

Regeneron Pharmaceuticals, Inc. and Sanofi Announce National Medical Products Administration Approves Dupixent in China

Regeneron Pharmaceuticals, Inc. and Sanofi Announce National Medical Products Administration Approves Dupixent in China

Regeneron Pharmaceuticals, Inc. to Report Q3, 2024 Results on Oct 31, 2024

Regeneron Pharmaceuticals, Inc. and Sanofi Announce U.S. Food and Drug Administration Approves Dupixent (Dupilumab) as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps

Senior VP of Finance & CFO recently sold US$6.4m worth of stock

Regeneron Pharmaceuticals, Inc Announces Ordspono (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma

Regeneron Provides Update on Biologics License Application for Linvoseltamab

Insider recently sold US$5.6m worth of stock

Second quarter 2024 earnings released: EPS: US$13.25 (vs US$9.05 in 2Q 2023)

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Approval in the European Union as the First-Ever Targeted Therapy for Patients with COPD

Regeneron Pharmaceuticals, Inc. Announces Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

Regeneron Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Regeneron Pharmaceuticals, Inc Announces Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine

Regeneron Pharmaceuticals, Inc. Announces 14-Month Median Follow-Up Data from the Pivotal Phase 1/2 Linker-MM1 Trial of Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma

Regeneron Pharmaceuticals, Inc and Sanofi Announces Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation

Regeneron Pharmaceuticals, Inc. Announces Positive New Results from an Ongoing Phase 1/2 Trial Evaluating its First-in-Class Costimulatory Bispecific Antibody, REGN7075 (EGFRxCD28)

Regeneron Pharmaceuticals, Inc. and Sanofi Presents Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in the New England Journal of Medicine

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application (sBLA) for Dupixent

Regeneron Pharmaceuticals, Inc. Announces Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness Within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks

New minor risk - Shareholder dilution

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) announces an Equity Buyback for $3,000 million worth of its shares.

First quarter 2024 earnings released: EPS: US$6.70 (vs US$7.64 in 1Q 2023)

Regeneron Pharmaceuticals, Inc. Announces Positive Pivotal Data from the Phase 1/2 LINKER-MM1 Trial of Linvoseltamab in Patients with Heavily Pre-Treated Multiple Myeloma

Regeneron Pharmaceuticals, Inc., Annual General Meeting, Jun 14, 2024

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) completed the acquiistion of R&D pipeline from 2seventy bio, Inc. (NasdaqGS:TSVT) for $20 million.

Regeneron Pharmaceuticals, Inc Provides Update on Biologics License Application for Odronextamab

Regeneron Pharmaceuticals, Inc.'s Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol

Regeneron Pharmaceuticals, Inc. Announces the Lancet Published One-Year Results from the Pivotal Pulsar and Photon Trials for EYLEA HD (Aflibercept) Injection 8 Mg

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts Dupixent®? (Dupilumab) Sbla for Treatment of Copd with Type 2 Inflammation

Regeneron Pharmaceuticals, Inc. Announces Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review

Regeneron Pharmaceuticals, Inc. and Sanofi Announces the Ministry of Health, Labor and Welfare in Japan Grants Marketing and Manufacturing Authorization for Dupixent (Dupilumab) for the Treatment of Chronic Spontaneous Urticaria

Insider recently sold US$7.6m worth of stock

Full year 2023 earnings released: EPS: US$37.05 (vs US$40.51 in FY 2022)

Regeneron Pharmaceuticals, Inc. Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma

Regeneron Pharmaceuticals, Inc. Appoints Jason Pitofsky as Controller, Expects to Occur on February 5, 2024

Regeneron Pharmaceuticals, Inc. and Sanofi Announce That U.S. Food and Drug Administration Approves Dupixent®? (Dupilumab) for the Treatment of Children Aged 1 Year and Older with Eosinophilic Esophagitis

Regeneron Pharmaceuticals, Inc. and Sanofi Announce U.S. Food and Drug Administration Updates the Label for Dupixent (Dpilumab)

Regeneron Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 02, 2024

Regeneron Pharmaceuticals, Inc. Announces New and Updated Data for Odronextamab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Pivotal Trial Showed Deep and the Potential of ctDNA to Predict Long-Term Outcomes

Regeneron Pharmaceuticals, Inc. Announces Updated Linvoseltamab Pivotal Data Demonstrated Strong Rates and Depth of Response in Patients with Heavily Pre-Treated Multiple Myeloma

Regeneron Pharmaceuticals, Inc. Announces Presentation of New and Updated Data on Multiple Combination Therapies from its Oncology Pipeline at ESMO IO Congress 2023

Regeneron Pharmaceuticals, Inc. Announces the Second Dupixent (Dupilumab) Investigational Phase 3 Chronic Obstructive Pulmonary Disease (COPD) Trial

Regeneron Pharmaceuticals, Inc. Announces the Second Dupixent (Dupilumab) Investigational Phase 3 Chronic Obstructive Pulmonary Disease (COPD) Trial

Third quarter 2023 earnings released: EPS: US$9.48 (vs US$12.31 in 3Q 2022)

Regeneron Pharmaceuticals, Inc. Announces Long-Term Outcomes and New Analyses of Pivotal Clinical Data for EYLEA®? HD (aflibercept) Injection 8mg

Regeneron Pharmaceuticals, Inc. Shares Preliminary Results Showing Gene Therapy Improves Auditory Responses in Child with Profound Genetic Hearing Loss

Regeneron Pharmaceuticals, Inc. and Sanofi Provide Update on Dupixent®? (Dupilumab) sBLA for Chronic Spontaneous Urticaria

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령

기업 분석 및 재무 데이터 현황

데이터 소스

분석 모델 및 눈송이

산업 및 부문 메트릭